Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Medtronic’s DBS Therapy for Epilepsy

Medtronic news release; 2018 May 1

Medtronic plc recently announced that the US Food and Drug Administration (FDA) has granted premarket approval for its Deep Brain Stimulation (DBS) therapy as adjunctive treatment for reducing the frequency of partial-onset epileptic seizures, in individuals ≥18 years who are refractory, or drug-resistant, to ≥3 antiepileptic medications. Medtronic plc is headquartered in Dublin, Ireland.

DBS therapy for epilepsy delivers controlled electrical pulses to a target in the brain called the anterior nucleus of the thalamus (ANT), which is part of a network involved in seizures. It uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to precisely targeted areas of the brain as adjunctive treatment for several neurological disorders.

Citation:

Medtronic receives FDA approval for deep brain stimulation therapy for medically refractory epilepsy. [news release]. May 1, 2018. Dublin, Ireland: Medtronic plc. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2345882. Accessed May 3, 2018.